Sugi Predict

Sugi Predict / Compounds / SCHEMBL831674

SCHEMBL831674

SCHEMBL831674

Cc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C1CC1)n2Cc1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C8 P10632 1/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ MAPT P10636 1/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ SCN5A Q14524 3/20 0.35
▸ SCN9A Q15858 3/20 0.35
▸ SCN2B O60939 1/20 0.35
▸ SCN1A P35498 1/20 0.35
▸ SCN1B Q07699 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ TPX2 Q9ULW0 1/20 0.35
▸ PTGDR2 Q9Y5Y4 2/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ PARG Q86W56 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ MOGAT2 Q3SYC2 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MGAM O43451 1/20 0.34
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831764 0.97 CYP2C8 (0.42) CYP2C8KMT2AMAPTMEN1SCN5A
SCHEMBL10256456 0.94 CYP2C8 (0.42) CYP2C8KMT2AMEN1SCN5ASCN9A
SCHEMBL830779 0.94 CYP2C8 (0.41) CYP2C8KMT2AMEN1SCN5ASCN9A
SCHEMBL831741 0.92 CYP2C8 (0.41) CYP2C8KMT2AMEN1SCN5ASCN9A
SCHEMBL862159 0.92 KMT2A (0.42) CYP2C8KMT2AMAPTMEN1SCN5A
SCHEMBL831761 0.91 CYP2C8 (0.41) CYP2C8KMT2AMEN1SCN5ASCN9A
SCHEMBL831751 0.91 CYP2C8 (0.41) CYP2C8KMT2AMAPTMEN1SCN5A
SCHEMBL831380 0.91 CYP2C8 (0.54) CYP2C8KMT2AMEN1SCN5ASCN9A
SCHEMBL831406 0.91 CYP2C8 (0.43) CYP2C8KMT2AMAPTSCN5ASCN9A
SCHEMBL831822 0.90 CYP2C8 (0.45) CYP2C8KMT2AMEN1SCN5ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197842-B1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORP (US) 2012-05-23 — — EP disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 — — US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
WO-2009032116-A1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885MAPT 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.